Literature DB >> 19079354

Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis.

Christopher Dye1.   

Abstract

Extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, now known to be present in 50 countries, heighten the threat posed by untreatable and fatal human tuberculosis (TB). To combat epidemics of drug-resistant TB, it is vital to understand why some resistant strains have greater reproductive fitness--a greater propensity to spread--than drug-susceptible strains. If public health malpractice has been a more important determinant of reproductive success than genetic mechanisms, then improved diagnosis and treatment could keep the frequency of resistant strains among TB cases low in any population. Recent data suggest that national TB control programmes that use existing drugs efficiently can postpone and even reverse epidemics of multidrug-resistant TB, although the effect of such programmes on XDR strains remains largely unknown.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19079354     DOI: 10.1038/nrmicro2048

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  67 in total

1.  Worldwide incidence of multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Marcos A Espinal; Catherine J Watt; Cyrille Mbiaga; Brian G Williams
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

Review 2.  Predicting antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero; Dan I Andersson
Journal:  Nat Rev Microbiol       Date:  2007-12       Impact factor: 60.633

3.  Does DOTS work in populations with drug-resistant tuberculosis?

Authors:  Kathryn DeRiemer; Lourdes García-García; Miriam Bobadilla-del-Valle; Manuel Palacios-Martínez; Areli Martínez-Gamboa; Peter M Small; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

4.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

Authors:  C Dye; G P Garnett; K Sleeman; B G Williams
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

5.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

Review 6.  Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Brian G Williams; Marcos A Espinal; Mario C Raviglione
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

8.  Beijing/W genotype Mycobacterium tuberculosis and drug resistance.

Authors: 
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

9.  The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia.

Authors:  Helen Suzanne Cox; Tanja Kubica; Daribay Doshetov; Yared Kebede; Sabine Rüsch-Gerdess; Stefan Niemann
Journal:  Respir Res       Date:  2005-11-08

10.  The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis.

Authors:  Maxine Caws; Guy Thwaites; Sarah Dunstan; Thomas R Hawn; Nguyen Thi Ngoc Lan; Nguyen Thuy Thuong Thuong; Kasia Stepniewska; Mai Nguyet Thu Huyen; Nguyen Duc Bang; Tran Huu Loc; Sebastien Gagneux; Dick van Soolingen; Kristin Kremer; Marianne van der Sande; Peter Small; Phan Thi Hoang Anh; Nguyen Tran Chinh; Hoang Thi Quy; Nguyen Thi Hong Duyen; Dau Quang Tho; Nguyen T Hieu; Estee Torok; Tran Tinh Hien; Nguyen Huy Dung; Nguyen Thi Quynh Nhu; Phan Minh Duy; Nguyen van Vinh Chau; Jeremy Farrar
Journal:  PLoS Pathog       Date:  2008-03-28       Impact factor: 6.823

View more
  51 in total

1.  Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data.

Authors:  Justin Manjourides; Hsien-Ho Lin; Sonya Shin; Caroline Jeffery; Carmen Contreras; Janeth Santa Cruz; Oswaldo Jave; Martin Yagui; Luis Asencios; Marcello Pagano; Ted Cohen
Journal:  Tuberculosis (Edinb)       Date:  2012-03-06       Impact factor: 3.131

2.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy.

Authors:  Andrew F Read; Troy Day; Silvie Huijben
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 3.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 4.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

Review 5.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

6.  Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis.

Authors:  Shaobin Shang; Marisa Harton; Marcela Henao Tamayo; Crystal Shanley; Gopinath S Palanisamy; Megan Caraway; Edward D Chan; Randall J Basaraba; Ian M Orme; Diane J Ordway
Journal:  Tuberculosis (Edinb)       Date:  2011-07-06       Impact factor: 3.131

7.  Biochemical characterization of the maltokinase from Mycobacterium bovis BCG.

Authors:  Vítor Mendes; Ana Maranha; Pedro Lamosa; Milton S da Costa; Nuno Empadinhas
Journal:  BMC Biochem       Date:  2010-05-27       Impact factor: 4.059

8.  Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Authors:  Crystal A Shanley; Gregory C Ireton; Susan L Baldwin; Rhea N Coler; Steven G Reed; Randall J Basaraba; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2013-09-07       Impact factor: 3.131

9.  CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice.

Authors:  Kyrie Felio; Hanh Nguyen; Christopher C Dascher; Hak-Jong Choi; Sha Li; Michael I Zimmer; Angela Colmone; D Branch Moody; Michael B Brenner; Chyung-Ru Wang
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

Review 10.  The past and future of tuberculosis research.

Authors:  Iñaki Comas; Sebastien Gagneux
Journal:  PLoS Pathog       Date:  2009-10-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.